INS and diabetes mellitus: One approach involves redirecting T effector cells to Tregs by employing FoxP3 engineering while simultaneously utilizing CAR technology to specifically target T cells to insulin, thereby reducing autoimmune attacks on pancreatic beta cells and preserving insulin production in patients with diabetes.